Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
1.250
+0.020 (1.63%)
At close: Mar 9, 2026, 4:00 PM EDT
1.230
-0.020 (-1.58%)
After-hours: Mar 9, 2026, 7:58 PM EDT
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
90
Market Cap
163.08M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.07M |
| Zentalis Pharmaceuticals | 26.87M |
| Innate Pharma | 14.84M |
| Caribou Biosciences | 11.16M |
| Tonix Pharmaceuticals Holding | 10.30M |
| Fate Therapeutics | 6.65M |
| Rani Therapeutics Holdings | 1.20M |
IMUX News
- 6 days ago - Immunic to Participate in Investor Conferences in March - PRNewsWire
- 11 days ago - Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 20 days ago - Immunic Announces Closing of Oversubscribed Private Placement Financing - PRNewsWire
- 24 days ago - Immunic Stock Jumps After Pricing $400 Million Private Placement - Benzinga
- 24 days ago - Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company - PRNewsWire
- 4 weeks ago - Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - PRNewsWire
- 2 months ago - Immunic Highlights 2025 Accomplishments and Upcoming Milestones - PRNewsWire
- 3 months ago - Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December - PRNewsWire